We publish no single base value for Bio-Techne. Our valuation methods put it between $26.67 and $53.50 a share. The valuation code's reason: no point fair value: the two anchors behind it compound the same growth rate and differ only in how they end — a perpetuity at the terminal rate against a multiple on the final year — so the midpoint between them measures terminal treatment rather than what the business is worth. The published range is the same reading with the false precision removed: read it as the span the method supports, and treat neither edge as a point estimate.
| Method | Value | vs price | Basis |
|---|---|---|---|
| Discounted cash flow | $26.67 | -63.4% | free cash flow $308.20m, growth 0.94% for 5 years, then fading to 3% over 5 more, discounted at 10.21%; plus net cash $1.97 a share; stress floor $20.93 |
| Exit multiple (P/E) | $53.50 | -26.6% | earnings per share $2.03 valued at 39.35× (the stock's own median P/E) in 5 years, discounted back |
| Sum of the parts | — | — | no sum of the parts: this run holds no segment disclosure for the name |
| Price to sales | — | — | not reached: the cash-flow or earnings methods produced an anchor, so this fallback was not run |
| Tangible book | — | — | used only for lenders, where book value is the business |
| Price to FFO (REITs) | — | — | used only for REITs |
Each working is rebuilt by code from the valuation's own figures and checked against the published value.
The discount rate:
| Risk-free rate | 5.13% (10-year US Treasury yield) |
| Company's own beta | 1.30 (5 years of monthly returns against the S&P 500; standard error 0.28) |
| Peer beta | 1.17 (median of 8 S&P 500 Life Sciences Tools & Services companies) |
| Blend of own and peers | 1.19 (22% own, 78% peers, weighted by how precisely the company's own beta is measured) |
| Adjusted beta | 1.13 (0.67 × 1.19 + 0.33, pulled toward the market's 1.0) |
| Equity risk premium | 4.5% |
| Discount rate = risk-free + adjusted beta × premium | 10.21% |
Free cash flow grows 0.94% a year for 5 years, then fades in equal steps toward 3% over 5 more; each year is discounted by 1 ÷ (1 + rate)^year:
| Year | Growth | Free cash flow | Discount factor | Present value |
|---|---|---|---|---|
| Now | — | $308.20m | — | — |
| Year 1 | 0.94% | $311.09m | 0.9073 | $282.26m |
| Year 2 | 0.94% | $314.02m | 0.8232 | $258.51m |
| Year 3 | 0.94% | $316.97m | 0.7469 | $236.75m |
| Year 4 | 0.94% | $319.95m | 0.6777 | $216.83m |
| Year 5 | 0.94% | $322.96m | 0.6149 | $198.58m |
| Year 6 | 1.28% | $327.10m | 0.5579 | $182.49m |
| Year 7 | 1.63% | $332.42m | 0.5062 | $168.27m |
| Year 8 | 1.97% | $338.97m | 0.4593 | $155.68m |
| Year 9 | 2.31% | $346.81m | 0.4167 | $144.52m |
| Year 10 | 2.66% | $356.03m | 0.3781 | $134.61m |
| Terminal value = year-10 cash flow × (1 + 3%) ÷ (10.21% − 3%) | $5.08bn |
| Terminal value in today's money | $1.92bn |
| Present value of years 1–10 | $1.98bn |
| Total present value | $3.90bn |
| Shares outstanding | 157.93m |
| Cash flows per share = total ÷ shares | $24.70 |
| Plus net cash per share | $1.97 |
| Value per share | $26.67 |
How the DCF value moves with the discount rate and the starting growth (the middle cell is the published value):
| Discount rate | Growth -4.06% | Growth 0.94% | Growth 5.94% |
|---|---|---|---|
| 9.21% | $23.08 | $30.54 | $40.54 |
| 10.21% | $20.39 | $26.67 | $35.04 |
| 11.21% | $18.35 | $23.73 | $30.89 |
The same DCF at each beta, starting growth unchanged:
| Beta | Value | Discount rate | DCF value |
|---|---|---|---|
| Company's own beta | 1.30 | 10.98% | $24.36 |
| Peer beta | 1.17 | 10.39% | $26.08 |
| Adjusted beta (used) | 1.13 | 10.21% | $26.67 |
Earnings per share grow on the same fading path as the DCF:
| Year | Growth | Earnings per share |
|---|---|---|
| Now | — | $2.03 |
| Year 1 | 0.94% | $2.05 |
| Year 2 | 1.46% | $2.08 |
| Year 3 | 1.84% | $2.12 |
| Year 4 | 2.13% | $2.16 |
| Year 5 | 2.35% | $2.21 |
| Earnings per share in year 5 | $2.21 |
| Exit P/E (the stock's own median P/E) | 39.35× |
| Value in 5 years = earnings × P/E | $87.02 |
| Discounted at 10.21% over 5 years: ÷ 1.6263 | $53.50 |
We publish no single base value for Bio-Techne. Our valuation methods put it between $26.67 and $53.50 a share. The valuation code's reason: no point fair value: the two anchors behind it compound the same growth rate and differ only in how they end — a perpetuity at the terminal rate against a multiple on the final year — so the midpoint between them measures terminal treatment rather than what the business is worth. The published range is the same reading with the false precision removed: read it as the span the method supports, and treat neither edge as a point estimate.
One-year price simulation: a 10% chance the price is below $78.50 and a 10% chance it is above $82.84 in a year, from 2.09% volatility. The simulation assumes the price drifts up at our discount rate of 10.21% a year.
At $72.84 the price implies free cash flow growing 19.2% a year for five years and then fading toward 3% over five more; its revenue has grown 0.9%.
| Week | Price | Base value |
|---|---|---|
| 2 Oct 2026 | $72.40 | — |
| 9 Oct 2026 | $72.46 | — |
| 16 Oct 2026 | $72.57 | — |
| 23 Oct 2026 | $72.55 | — |
| 30 Oct 2026 | $72.66 | — |
| 6 Nov 2026 | $72.78 | — |
| 12 Nov 2026 | $72.84 | — |
Data as of 12 Nov 2026; financials to 30 Sep 2026. Sources: company filings via EODHD, SEC EDGAR, US Treasury. How these values are computed. Not investment advice.
Run a full Desk Run on TECH · Bio-Techne company page · Call and put prices